Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

The Lancet

Volumn 395, Issue 10234, 2020, Pages 1407-1409

  Feldmann, Marc ^a   Maini, Ravinder N ^b   Woody, James N ^c   Holgate, Stephen T ^d   Winter, Gregory ^e   Rowland, Matthew ^f   Richards, Duncan ^f   Hussell, Tracy ^g  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Laterell Venture Partners   (United States)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^e TRINITY COLLEGE   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANGIOTENSIN CONVERTING ENZYME 2; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT RESPIRATORY DISTRESS SYNDROME; CONVALESCENCE; CORONAVIRUS DISEASE 2019; DRUG RESEARCH; DRUG SAFETY; EARLY INTERVENTION; HOST CELL; HUMAN; LUNG ALVEOLUS CELL TYPE 2; MORTALITY; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TREATMENT OUTCOME; UPREGULATION; VIRUS ENTRY; VIRUS PNEUMONIA;

EID: 85083308281     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(20)30858-8     Document Type: Note

References (28)

1. European Centre for Disease Prevention and Control. COVID-19 situation update worldwide, as of 8 April 2020. https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases. (Accessed 8 April 2020)
2. Letko, M, Marzi, A, Munster, V, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 5 (2020), 562–569.
3. Xu, Z, Shi, L, Wang, Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8 (2020), 420–422.
4. Gerriets, V, Bansal, P, Khaddour, K, Tumor necrosis factor (TNF) inhibitors. 2020, Publishing, Treasure Island, FL.
5. Wang, L, He, W, Yu, X, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect, 2020 DOI:10.1016/j.jinf.2020.03.019 published online March 30.
6. Liu, J, Zheng, X, Tong, Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol 92 (2020), 491–494.
7. Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506.
8. Gong, J, Dong, H, Xia, Q, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia. MedRxiv, 2020 published online Feb 27. https://doi.org/10.1101/2020.02.25.20025643 (preprint).
9. Michot, JM, Albiges, L, Chaput, N, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol, 2020 DOI:10.1016/j.annonc.2020.03.300 published online April 2.
10. Conti, P, Ronconi, G, Caraffa, A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents, 2020 DOI:10.23812/CONTI-E published online March 14.
11. Hussell, T, Pennycook, A, Openshaw, PJ, Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol 31 (2001), 2566–2573.
12. Clark, J, Vagenas, P, Panesar, M, Cope, AP, What does tumour necrosis factor excess do to the immune system long term?. Ann Rheum Dis 64:suppl 4 (2005), iv70–iv76.
13. Brennan, FM, Chantry, D, Jackson, A, Maini, R, Feldmann, M, Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2 (1989), 244–247.
14. Fong, Y, Tracey, KJ, Moldawer, LL, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 170 (1989), 1627–1633.
15. Charles, P, Elliott, MJ, Davis, D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163 (1999), 1521–1528.
16. Paleolog, EM, Young, S, Stark, AC, McCloskey, RV, Feldmann, M, Maini, RN, Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41 (1998), 1258–1265.
17. Majewska, E, Paleolog, E, Baj, Z, Kralisz, U, Feldmann, M, Tchorzewski, H, Role of tyrosine kinase enzymes in TNF-alpha and IL-1 induced expression of ICAM-1 and VCAM-1 on human umbilical vein endothelial cells. Scand J Immunol 45 (1997), 385–392.
18. Feldmann, M, Maini, RN, Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 19 (2001), 163–196.
19. Dvorak, HF, Brown, LF, Detmar, M, Dvorak, AM, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146 (1995), 1029–1039.
20. Taylor, PC, Peters, AM, Paleolog, E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 43 (2000), 38–47.
21. McCullers, JA, The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol 12 (2014), 252–262.
22. Collins, J, COVID-19 pneumonia. MRI Online. https://mrionline.com/diagnosis/covid-19-pneumonia, 2020. (Accessed 8 April 2020)
23. Goulding, J, Godlee, A, Vekaria, S, Hilty, M, Snelgrove, R, Hussell, T, Lowering the threshold of lung innate immune cell activation alters susceptibility to secondary bacterial superinfection. J Infect Dis 204 (2011), 1086–1094.
24. Galloway, JB, Hyrich, KL, Mercer, LK, Dixon, WG, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50 (2011), 124–131.
25. Abraham, E, Wunderink, R, Silverman, H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273 (1995), 934–941.
26. Cohen, J, Carlet, J, INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24 (1996), 1431–1440.
27. Richter, A, Listing, J, Schneider, M, et al. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis 75 (2016), 1667–1673.
28. Fisher, CJ Jr., Agosti, JM, Opal, SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334 (1996), 1697–1702.